Endovia Health Sciences, Inc.
EDVA NYSE· Beverages
Last close · Oct 26, 2026
$0.16
KIRA · Stoqly’s AI analyst, in plain words
- Endovia Health Sciences, Inc. had $0.1M of revenue in fiscal 2025, down 90.9% on the year before. Over five years, revenue changed −49.8% a year on average.
- Its operating margin was −19,406.6%, down 18,171.0 pts: of every 100 in sales, about −19,407 is left after running the business.
- Endovia Health Sciences, Inc. lost $25.2M in fiscal 2025.
- Endovia Health Sciences, Inc. has $0.3M more cash than debt.
Market cap
$0.5M
P/E
—
Revenue
$0.1M
Net income
−$25.2M
Free cash flow
—
Operating margin
−19,406.6%
Endovia Health Sciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−90.9%
No. Sales fell 90.9% last year.
Does it make a profit?
−34,520.9%
No. It lost money last year.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Endovia Health Sciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 15, 2026
- Legal name
- Endovia Health Sciences, Inc.
- CIK
- 0001553788
Endovia Health Sciences, Inc. · EDVA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $11.3M | $18.1M | $18.9M | $0.8M | $0.1M |
| Revenue growth | 392.0% | 59.8% | 4.2% | −95.7% | −90.9% |
| Net interest income | −$0.4M | — | −$1.9M | −$3.7M | −$2.5M |
| Gross margin | 34.6% | 32.7% | 29.5% | −15.0% | 23.1% |
| Operating margin | −257.0% | −118.3% | −81.1% | −1,235.5% | −19,406.6% |
| Net income | −$29.1M | −$21.7M | −$21.0M | −$23.8M | −$25.2M |
| Net margin | −256.7% | −119.9% | −111.4% | −2,964.8% | −34,520.9% |
| Diluted EPS | −$1.02 | — | — | −$17.68 | −$11.97 |
| Cash | |||||
| Cash from operations | −$14.7M | −$14.0M | −$10.2M | −$7.3M | −$4.8M |
| Capital expenditure | $0.0M | $0.1M | $0.0M | $0.0M | — |
| Free cash flow | −$14.7M | −$14.1M | −$10.2M | −$7.3M | — |
| FCF margin | −129.9% | −78.2% | −54.1% | −911.8% | — |
| Share count change | 55.9% | 29.4% | −97.2% | 26.1% | 62.8% |
| Debt and strength | |||||
| Cash and short-term investments | $4.2M | $4.4M | $0.4M | $0.0M | $0.3M |
| Debt incl. finance leases | $0.0M | $2.5M | $0.5M | $2.0M | $0.0M |
| Shareholders' equity | $8.9M | $9.3M | −$5.6M | −$18.6M | −$15.3M |
| Current ratio | 1.3x | 2.1x | 0.3x | 0.1x | 0.0x |
| Interest coverage | −65.7x | −85.1x | −8.2x | −2.7x | −5.6x |
| Returns and quality | |||||
| Return on capital | −489.7% | −227.6% | — | — | — |
| Return on equity | — | −238.4% | −1,130.2% | — | — |
| Return on tangible equity | −964.5% | −514.7% | — | — | — |
| Piotroski F-score | 6 | 4 | 4 | 1 | 3 |
| Altman Z'' | −28.0 | −26.1 | −61.8 | −250.7 | −819.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Endovia Health Sciences, Inc. · EDVA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.16 a share, the company is worth $0.5M.
Source: SEC EDGAR XBRL filings (CIK 0001553788). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.